Market News

MacroGenics Teams up with Gilead

Biopharmaceutical company MacroGenics’ (NASDAQ:MGNX) stock is soaring today after it announced a collaboration with Gilead Sciences (NASDAQ:GILD) for the development of bispecific antibodies.

Under the agreement, Gilead can choose to license MGD024, a potential treatment for certain blood cancers.

Further, MGNX will receive $60 million in upfront payment and stands to potentially receive up to $1.7 billion in various milestone payments apart from royalties in the double digits under this collaboration.

Is MGNX Stock a Buy?

The consensus rating for MGNX remains a Strong Buy based on seven Buys and Two Holds. Further, the average analyst price target of $9.29 points to a massive 154.17% potential upside in the stock.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More